USPSTF: Screen Women of Reproductive Age for Intimate Partner Violence

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

TUESDAY, June 24, 2025 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening women of reproductive age for intimate partner violence (IPV). These findings form the basis of a final recommendation statement published online June 24 in the Journal of the American Medical Association.

Cynthia Feltner, M.D., M.P.H., from the University of North Carolina at Chapel Hill, and colleagues reviewed the evidence on screening and interventions for IPV and caregiver abuse among adults. Data were included from 35 studies, with 18,358 participants. The researchers found that three randomized clinical trials (RCTs) comparing IPV screening with no screening found no significant reduction in IPV or benefit for other outcomes over three to 18 months, and no harms of screening were seen in two trials. In nine studies that assessed nine tools to detect past-year IPV exposure among women, sensitivity ranged from 26 to 87 percent and specificity from 80 to 97 percent. One RCT found a significant reduction in IPV with multiple perinatal home visits, and one found significantly fewer recurrent episodes of IPV with behavioral counseling for multiple risks. There were no studies found that examined screening or interventions for caregiver abuse among older or vulnerable adults.

Based on these findings, the USPSTF recommends that clinicians screen women of reproductive age, including those who are pregnant and postpartum, for IPV (B recommendation). For older or vulnerable adults, the current evidence is insufficient to assess the balance of benefits and harms of screening for caregiver abuse and neglect (I statement).

"Screening women of reproductive age is an effective way for clinicians to connect those who need it to care," USPSTF member David Chelmow, M.D., said in a statement.

Evidence Report (subscription or payment may be required)

Final Recommendation Statement (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords